Hospital Clinic Barcelona
Jordi Bruix is Professor of Medicine at the University of Barcelona and director of the BCLC (Barcelona Clinic Liver Cancer) group within the Hepatology Unit of the Hospital Clinic. I Barcelona.
Member of the European Liver Study Association (EASL) and the American Liver Disease Study Association (AASLD), he founded the International Liver Cancer Association (ILCA) of which he was President from 2006 to 2009. He has been Associate Editor of publications like the Journal of Hepatology, Liver Transplantation and Hepatology and has been appointed editor-in chief of Seminars in Liver Disease.
Prof. Bruix has been the leading investigator in studies and trials that have changed clinical practice in the field of hepatocellular carcinoma, including the development of diagnostic criteria, prognostic models and validation of the efficacy of chemoembolization, of Sorafenib and Regorafenib.
He has developed the BCLC strategy for staging and treatment which has been adopted by several international organisations.
Author of over 250 original research papers, he has led the development of the evidence-based clinical practice guidelines of EASL, AASLD and the World Organization for Gastroenterology (WGO). Prof. Bruix was awarded with the EASL Recognition Award in 2016.